X‐linked dominant protoporphyria: The first reported Japanese case

A 12‐year‐old boy with photosensitivity since 3 years of age presented with small concavities on both cheeks, the nasal root and the dorsal surface of both hands. According to the clinical features, erythropoietic protoporphyria (EPP) was suspected. Urine and blood samples were tested for porphyrin derivatives, which revealed a markedly elevated level of erythrocyte protoporphyrin (EP) and a diagnosis of EPP was made. The patient's mother had no photosensitivity, however, lesions appearing slightly as small scars were found on the dorsum of her right hand; his elder sister and father showed no rash. The EP levels were elevated in samples from his mother and mildly elevated in those from his elder sister and father. To obtain a definitive diagnosis, genetic analyses were performed using samples from all family members, which revealed no mutations in the ferrochelatase‐encoding gene (FECH), which is responsible for EPP. Instead, a pathological mutation of the 5‐aminolevulinic acid synthase‐encoding gene (ALAS2) was identified in samples from the patient, his mother and his elder sister, confirming a definitive diagnosis of X‐linked dominant protoporphyria (XLDPP). This is the first Japanese family reported to have XLDPP, demonstrating evidence of the condition in Japan. In addition, because XLDPP is very similar to EPP in its clinical aspects and laboratory findings, a genetic analysis is required for the differential diagnosis.

[1]  R. Desnick,et al.  X‐chromosomal inactivation directly influences the phenotypic manifestation of X‐linked protoporphyria , 2016, Clinical genetics.

[2]  A. Anstey,et al.  X‐linked dominant protoporphyria: a new porphyria , 2014, Clincal and Experimental Dermatology.

[3]  J. Frank,et al.  Photosensitivity in the elderly-think of late-onset protoporphyria. , 2013, The Journal of investigative dermatology.

[4]  H. Bonkovsky,et al.  Loss-of-Function Ferrochelatase and Gain-of-Function Erythroid-Specific 5-Aminolevulinate Synthase Mutations Causing Erythropoietic Protoporphyria and X-Linked Protoporphyria in North American Patients Reveal Novel Mutations and a High Prevalence of X-Linked Protoporphyria , 2013, Molecular Medicine.

[5]  S. Ducamp,et al.  Molecular and functional analysis of the C-terminal region of human erythroid-specific 5-aminolevulinic synthase associated with X-linked dominant protoporphyria (XLDPP). , 2013, Human molecular genetics.

[6]  R. Desnick,et al.  Molecular Expression and Characterization of Erythroid-Specific 5-Aminolevulinate Synthase Gain-of-Function Mutations Causing X-Linked Protoporphyria , 2013, Molecular Medicine.

[7]  E. Neufeld,et al.  Systematic molecular genetic analysis of congenital sideroblastic anemia: Evidence for genetic heterogeneity and identification of novel mutations , 2010, Pediatric blood & cancer.

[8]  Joanne,et al.  C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. , 2008, American journal of human genetics.

[9]  H. Willard,et al.  X-inactivation profile reveals extensive variability in X-linked gene expression in females , 2005, Nature.

[10]  S. Sassa,et al.  Porphyrias in Japan: Compilation of All Cases Reported through 2002 , 2004, International journal of hematology.

[11]  D. Reinberg,et al.  Epigenetic Dynamics of Imprinted X Inactivation During Early Mouse Development , 2004, Science.